Malignant Intestinal Neoplasm

This variant (V273fs), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a 61 year-old male patient (sLS-27) with suspected Lynch Syndrome (L… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

To assess the effects of MSH3 status on chemosensitivity, MSH3-deficient and MSH3-proficient HCT116 cells were treated with oxaliplatin, SN-38 (irinotecan metabolite), and 5-FU. Parental MSH3-deficien… (full text at CIViC)

PMID 23724141 · Park et al., 2013 · Open in CIViC

This variant (I891fs), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 79 year-old male patient with suspected Lynch Syndrome (LS). The patient was t… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. … (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS.

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

MSH6 R1242C (c.3724C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 53 year old male patient with suspected Lynch Syndrome (LS). The patient … (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant (R1242H), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 79 year-old male patient (sLS-37) with suspected Lynch Syndrome (LS). The pati… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This study looked specifically at the prognostic significance of Microsatellite Instability High (MSI-H) in sporadic Australian Clinico Pathological Stage C colorectal cancer in patients from a single… (full text at CIViC)

PMID 10971428 · Wright et al., 2000 · Open in CIViC

47 patients with locally advanced rectal cancer were treated with dostarlimab. 41 completed treatment and achieved a clinical complete response. No patients experienced local or distant disease recurr… (full text at CIViC)

Open in CIViC

Thirty-five MSI-H/dMMR patients were treated with anti-PD-1 therapy. Of the 35 patients, 10 patients harboured B2M mutations, and 8 patients harboured JAK mutations. A low TMB score was noted in patie… (full text at CIViC)

PMID 35343934 · Zhang et al., 2022 · Open in CIViC

Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and 3.25 times more likely not to experience relapse (95%… (full text at CIViC)

PMID 26693073 · Nikas et al., 2015 · Open in CIViC

In a retrospective cohort analysis of colon adenocarcinoma treated with PD-1/PD-L1 immune checkpoint inhibitors from the MSKCC ICIs-treated COAD dataset (n = 76; NCOA3-mutant n = 7, NCOA3-wild-type n … (full text at CIViC)

PMID 40215778 · Liu et al., 2025 · Open in CIViC

shRNA-mediated NME1 knockdown significantly increased fluorouracil sensitivity in HCT-116, HT-29, and SW620 colorectal cancer cells. The study reports 4- to 13-fold decreases in IC50 across the NME1, … (full text at CIViC)

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

NOTCH1 amplifications (as determined by FISH) were significantly (log-rank p = 0.025) associated with worse survival in a cohort of 116 patients with colorectal cancer.

PMID 26152787 · Arcaroli et al., 2016 · Open in CIViC

NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622… (full text at CIViC)

PMID 26152787 · Arcaroli et al., 2016 · Open in CIViC

Finally, treatment of CRC cells with anti-Notch2/3 antibody increased Numb protein while significantly reducing formation of spheroids in both MICOL-14tum cells and primary tumor cultures. This novel … (full text at CIViC)

PMID 24525742 · Pastò et al., 2014 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

Statistical analysis showed that the inverse relationship between COUP-TF II and SMAD4 expression was shown in 112 different patients with Colorectal Cancer(CRC)(45 COUP-TF II-positive/SMAD4-negative … (full text at CIViC)

PMID 26261604 · Wang et al., 2015 · Open in CIViC

In an in vitro study, an OXCO-2 cell line expressing NRAS G12C mutation demonstrated acquired resistance after low level cetuximab exposure compared to OXCO-2 parental cells expressing NRAS wild-type.… (full text at CIViC)

PMID 24553387 · Misale et al., 2014 · Open in CIViC

Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC)

PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC

In an in vitro study, an OXCO-2 cell line expressing NRAS G12D mutation demonstrated acquired resistance after low level cetuximab exposure compared to OXCO-2 parental cells expressing NRAS wild-type.… (full text at CIViC)

PMID 24553387 · Misale et al., 2014 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC

In an in vitro study, a DiFi colorectal cancer cell line stably expressing NRAS G12V mutation demonstrated resistance to cetuximab treatment compared to DiFi cells expressing wild-type NRAS. Resistanc… (full text at CIViC)

PMID 22797062 · Kasper et al., 2013 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC

In an in vitro study, an OXCO-2 cell line expressing NRAS G13D mutation demonstrated acquired resistance after low level cetuximab exposure compared to OXCO-2 parental cells expressing NRAS wild-type.… (full text at CIViC)

PMID 24553387 · Misale et al., 2014 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.

PMID 24666267 · Therkildsen et al., 2014 · Open in CIViC

A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC)

PMID 22586653 · Bertotti et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC